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Development of a Radioimmunoassay for Hog Pancreatic 
Kallikrein and its Application in Pharmacological Studies 
E. F I N K 
The estimation of hog pancreatic Kallikrein is conventionally performed by pro-
teolytic assays using either synthetic substrates or the natural substrate kininogen. 
However, these assays are not specific for Kallikrein in that they detect other pro-
teases, too. Since we needed an assay suitable for studies in which the pharmacologi-
cal effects after administration of Kallikrein are to be associated with the concentra-
tion of the enzyme in blood and tissues where other proteases might be present we 
developed a highly sensitive and specific radioimmunoassay for hog pancreatic Kal-
likrein. 
The radioimmunoassay method is based on the competitive inhibition of the bind-
ing of labelled antigeii to its specific antibody by the unknown or by the unlabelled 
antigen used as a standard. The sensitivity of the method results from the use of 
radioisotopes and its specificity from the immunological reaction between the anti-
gen and its antibody. 
Materials and methods 
The Kallikrein used for radioiodination and as standard in the R I A was a highly 
purified neuraminidase treated preparation (1). Rabbit anti-Kallikrein serum was 
kindly provided by Bayer A G . 
As second antiserum donkey anti-rabbit IgG serum, Welcome Company, was 
used. 
Na 1 2 5 I was purchased from Farbwerke Hoechst A G , Frankfurt/Main. 
Buffers: buffer A : 0.015M N a H 2 P 0 4 , 0.15M NaCl, 0.02% Merthiolat, 0.2% 
bovine serum albumin, 0 .01MEDTA, pH 7.4. Buffer B: 0.015MNaH 2 PO 4 ,0.15 M 
NaCl, 0.02% Merthiolat, 4% bovine serum albumin, pH 7.4. Buffer C: 0.015M 
N a 2 H P 0 4 , 0.15M NaCl, pH 7.4. 
Radioimmunoassay conditions 
Anti-Kallikrein serum was diluted with buffer B, dilutions of Kallikrein standard 
samples, unknowns, anti-rabbit IgG serum and 1 2 5I-Kallikrein were prepared with 
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buffer A , the 1 2 5I-Kallikrein dilution (250000 cpm/ml) contained 70 ug/ml rabbit 
IgG. The incubation mixtures were set up according to the following Table 1: 
Table 1. Incubation mixtures. 
Buffer A 
serum 
Ml 
Buffer B 
serum 
Ml 
Sample 
serum 
Ml 
Anti-Kallikrein 
serum 
Hi 
125I-Kallikrein 
serum 
Ml 
N 200 100 — — 100 
Bo 200 - - 100 100 
Samples 100 - 100 100 100 
After an incubation period of 24-48 h 100 ul of the dilution of the second an-
tiserum were added followed by 0.5 ml buffer A after 30 min. After 10 min centrifu-
gation at 6000g the supernatant was removed by aspiration and the precipitates were 
counted in a well type gamma counter. 
P r e p a r a t i o n of 1 2 5 I - K a l l i k r e i n 
For the labelling of Kallikrein with Na 1 2 5 I a modification (2) of the chloramine-T 
method of GREENWOOD and H U N T E R (3) was employed. The labelled Kallikrein was 
separated from free iodine by gel filtration of the reaction mixture through a 
Sephadex G-75 column (1.3 x 15cm) equilibrated with buffer C. Fractions of 0.8ml 
were collected. The 5 fractions of the Kallikrein peak with the highest radioactivity 
were combined and diluted with buffer A to a concentration of 250000 cpm/ml. A 
specific activity between 40 and 130 uCi/ug was achieved. The preparations were 
used in the RIA for up to 4 weeks. 
Results and discussion 
Radioimmunoassay 
Fig. 1 shows the binding of 1 2 5I-Kallikrein (28000 cpm) to antibody after incuba-
tion at 21°C for 24 hours using increasing dilutions of the antiserum. More than 80% 
of the 1 2 5I-Kallikrein were bound indicating the high quality of the antiserum. 
In order to find the optimal incubation conditions the kinetics of the binding of 
1 2 5I-Kallikrein to the antibody was studied at 8, 22 and 37°C. The results are sum-
marized in Fig. 2. The lowest reaction rate is observed at 8°C. At 37°C the initial 
binding rate is insignificantly higher than at 22°C and slows down after 8 h. At 
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Fig. 1. Antiserum titration curve for 125I-Kallikrein (hog pancreas). For incubation conditions see text. 
equilibrium, which is reached after different incubation periods for the different 
temperatures, the amount of bound radioactivity is highest at 22°C. Incubation 
periods longer than 72h result in a significant decrease of binding. We interpret this 
phenomenon by loss of immunologic reactivity of the 1 2 5I-Kallikrein and/or the anti-
body. Based on these studies incubation at 22°C for 24—48h was chosen for the 
routine RIA. 
For the separation of Kallikrein-antibody complex from free Kallikrein by the 
second antibody method similar studies showed that maximum precipitation was 
achieved already after 15-min incubation at 22°C. 
The evaluation of the R I A was done either manually using logit-log graph paper 
(4; Fig. 3 shows a typical standard curve) or by means of a computer employing the 
spline approximation method (5). The lowest level of detection for hog pancreatic 
Kallikrein in the R I A was between 40 and 300 pg per 100 ul sample volume, depend-
ing on the quality of the labelled Kallikrein and the incubation conditions. The coef-
ficient of variation for triplicates was usually between 6 and 14%. 
Measurement of K a l l i k r e i n i n serum 
Since in the pharmacological studies it would be necessary to measure the Kalli-
krein concentration in the serum of dogs we investigated the influence of dog serum 
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Fig. 3. Standard curve for the radioimmunoassay of hog pancreatic Kallikrein. For incubation conditions 
see text. The data are presented in the form of the logit-log plot (4). 
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Fig. 4. Standard curve for the radioimmunoassay of hog pancreatic Kallikrein in the presence of dog 
serum. • — • without serum, O O and • • in the presence of 20 ul and 100 ul serum. For incuba-
tion conditions see text. 
on the RIA. Fig. 4 demonstrates that the presence of serum has indeed an influence, 
the slope of the standard curve depends on the amount of serum added to the incuba-
tion mixture. Therefore, if serum samples are to be assayed, the standard curve has to 
be set up under addition of the same volume of serum to the standard incubation mix-
tures as applied in the unknowns. The influence of serum on the immunoreactivity of 
Kallikrein in the RIA may be caused by complex formation with serum inhibitors 
and/or by unspecific interactions of serum components. 
The formation of a complex of Kallikrein with (a) serum component(s) was de-
monstrated by gel filtration experiments. A mixture of Kallikrein and dog serum was 
applied to a Sephacryl S-200 column and the eluate was tested by R I A . Two peaks 
were detected, one in the normal elution position of Kallikrein, the other approxi-
mately in the position of the albumin peak. This second peak might represent the 
complex of Kallikrein with a rantitrypsin. 
Some proteases were checked for cross-reactivity by the RIA; hog-trypsin and 
bovine trypsin and chymotrypsin showed no cross-reactivity at all whereas hog sub-
mandibular and urinary Kallikreins had immunoreactivities comparable to the pan-
creatic Kallikrein. We have not yet investigated Kallikreins of other species. 
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Pharmacological studies 
The R I A for hog pancreatic Kallikrein offers the possibility to study the long 
known pharmacological effects of Kallikrein in relation to the Kallikrein concentra-
tion in the blood. As already described by FREYand K R A U T (6) and FREY, W E R L E and 
SACKERS (7) intravenous injection of Kallikrein causes an immediate drop of the 
mean blood-pressure which is due to the release of kinin from kininogen. If Kalli-
krein is applied intramuscularly the response of the blood-pressure is delayed and is 
less dramatical. 
Fig. 5 summarizes the changes of blood pressure and kininogen concentration in 
plasma in relation to the Kallikrein concentration in serum after intravenous injec-
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Fig. 5. Changes of mean blood-pressure and plasma kininogen concentration in relation to the Kallikrein 
concentration after intravenous injection. For details see text. 
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Fig. 6. Response of the mean blood-pressure in relation to the Kallikrein concentration after intramuscu-
lar injection. For details see text. 
tion. After injection of 0.5mg Kallikrein into the left femoral vein of a dog (15 kg 
body weight, pentobarbital anesthesia) samples of blood were taken from the right 
femoral vein. The highest concentration of Kallikrein was found in the sample ob-
tained within 1 min after injection. The concentration dropped rapidly within 6 min 
from 530 ng/ml to 300 ng/ml. After this initial phase the half-life of Kallikrein was 
approximately 1 hour. After repeated injections of Kallikrein basically identical 
elimination kinetics were observed. The kininogen concentration on the upper pan-
nel is expressed as ng bradykinin equivalents releasable per mg plasma protein by in-
cubation of plasma samples with trypsin. It was measured in the bioassay with the iso-
lated rat uterus (8) using synthetic bradykinin as reference. Immediately after the 
Kallikrein injection the kininogen concentration dropped from 600 ng bradykinin 
equivalents per mg plasma protein to 350 ng. This level was relatively constant for 2h 
in spite of the presence of relatively high concentrations of immunologically active 
Kallikrein, an indication that the Kallikrein circulating in the blood must be present 
mainly as an enzymatically inactive form. A second injection of Kallikrein caused a 
drop of the kininogen concentration below the level of detection. The response of the 
mean blood-pressure, recorded from the carotid artery, indicates that at the time of 
the third injection there was still some kininogen present in the blood. 
After intramuscular injection of Kallikrein the maximum of the Kallikrein con-
centration in the blood is much lower and the time period necessary to reach it is 
longer than after intravenous injection (Fig. 6). The rate of the decrease of the Kal-
likrein concentration in the blood is comparable to the slow phase of elimination aft-
er intravenous injection. The blood-pressure reached a minimum within 5 min after 
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injection when the maximum of the Kallikrein concentration in the blood was not yet 
reached. After the initial phase the blood-pressure remained constant at a level 
somewhat lower than before injection. 
Concluding from the results presented here the radioimmunoassay for porcine 
pancreatic Kallikrein is a highly suitable tool for the study of the pharmacological ef-
fects of this enzyme. It is expected that it will be possible to get new insights into the 
action and fate of pancreatic Kallikrein in the organism by using this tool. 
Acknowledgements 
This work was generously supported by a grant of the Deutsche Forschungsgemeinschaft. 
The skilful technical assistance of Mrs. C. GÜTTEL is gratefully acknowledged. 
Anti-Kallikrein serum and hog pancreatic Kallikrein for pharmacological studies were kindly provided 
by Bayer AG, the highly purified Kallikrein used for iodination and as reference was a gift of Dr. 
F. FIEDLER. 
I am very grateful to Prof. P. C. SCRIBA for the kind permission to use the facilities of his laboratory for 
radioactive work. 
I am indebted to Dr. F. ERHARDT for his helpful discussions in developing the radioimmunoassay. 
I wish to thank very much Prof. H. FRITZ for his stimulating discussions and comments and for the in-
spiring atmosphere he creates in our department. 
References 
(1) FIEDLER, F.: Pig pancreatic kallikreins A and B. In: LORAND, E. (ed.): Methods in enzymology, Vol. 
45, 289-303, Academic Press, New York 1976. 
(2) ERHARDT, F . , I. MARSCHNER, R. C. PICKART, P. C. SCRIBA: Verbesserung und Qualitätskontrolle der 
radioimmunologischen Thyreotropin-Bestimmung. Z. klin. Chem. klin. Biochem. 1 1 : 381-387 
(1973). 
(3) GREENWOOD, F. C , W. M. HUNTER, J. GLOVER: The preparation of 131I-labeled human growth hor-
mon of high specific radioactivity. Biochem. J. 8 9 : 114-123 (1963). 
(4) RODBARD, D. , W. BRIDSON, P. L. RAYFORD: Rapid calculation of radioimmunoassay results. J . Lab. 
clin. Med. 74: 770-781 (1969). 
(5) MARSCHNER, I., F . ERHARDT, P. C. SCRIBA: Calculation of the radioimmunoassay standard curve by 
"spline function". In: Radioimmunoassay and related procedures in medicine, Vol. I, 111-122, 
IAEA, Vienna 1974. 
(6) FREY, E. K., H . KRAUT: Ein neues Kreislaufhormon und seine Wirkung. Naunyn-Schmiedeberg's 
Arch. exp. Path. Pharmak. 1 3 3 : 1-56 (1928). 
(7) FREY, E. K., E. WERLE, E. SACKERS: Über die Wirkung intravenöser und intramuskulärer Kallikrein-
injektionen beim Menschen. Z. ges. exp. Med. 9 6 : 404—413 (1935). 
(8) MANN, K., R. GEIGER, E. WERLE: A sensitive kinin liberating assay for kininogenase in rat urine, iso-
lated glomeruli and tubules of rat kidney. In: Adv. exp. Med. Biol. (BACK, N., F . SICUTERL G . L. 
HABERLAND, [eds.]) 70: 65-73, Plenum Press, New York 1976. 
